BioPharmX is pleased to announce unaudited stockholders’ equity of approximately $6,278,000 on a pro forma basis as of January 16, 2018. Subject to review by the NYSE American LLC, the Company believes it is back in compliance with the NYSE American’s continued listing standards.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.